– Bloomberg
Nurix Therapeutics Q3 EPS $(0.90) Beats $(0.98) Estimate, Sales $10.79M Miss $12.08M Estimate
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(0.98) by 8.16 percent. This is a 38.46 percent decrease over losses of $(0.65) per share from